Biotechnology Instruments Market is estimated to be valued at USD 68.22 Bn in 2025 and is expected to reach USD 127.95 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 9.4% from 2025 to 2032.
Advancements in genomics, proteomics, and molecular diagnostics are driving strong growth in the biotechnology instruments market. Pharmaceutical and healthcare sectors are actively adopting these instruments to meet the rising demand for precision medicine and address the growing burden of chronic diseases. Researchers are expanding their activities, while innovations like automation, AI integration, and lab-on-chip systems are boosting lab efficiency and accuracy.
|
Current Events |
Description and its impact |
|
Geopolitical Developments Affecting Biotechnology Instruments Supply Chains |
|
|
Technological Innovations and Integrations |
|
|
Economic and Funding Trends Influencing R&D and Market Growth |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
AI plays a transformative role in the biotechnology market by accelerating research, improving diagnostics, and enabling personalized medicine. Through machine learning and data analytics, AI helps identify patterns in complex biological data, speeding up drug discovery and development. In diagnostics, AI enhances accuracy by analyzing medical images, genetic data, and biomarkers. It also powers wearable biosensors for real-time health monitoring and chronic disease management.
In July 2025, Trinity Biotech plc, a biotechnology company specializing in diagnostics and diabetes management, announced CGM+, its next-generation AI-powered continuous glucose monitoring (CGM) system. Now in advanced development, CGM+ is a wearable biosensor platform that integrates multi-sensor data and real-time analytics.
Hospitals & Healthcare Facilities dominates the overall market with an estimated share of 45.6% in 2025. Healthcare facilities and hospitals are increasing their use of biotechnology instruments to meet the growing demand for fast and accurate diagnostics, particularly for chronic and infectious diseases. They are adopting advanced tools to support personalized treatments through genetic and molecular diagnostics. Innovations in point-of-care testing, automation, and imaging are helping medical teams improve patient care and streamline clinical workflows. As hospital admissions rise and the population ages, healthcare providers are investing more in efficient diagnostic and monitoring technologies. For instance, in January 2024, Roche, the global leader in biotechnology and in-vitro diagnostics, inaugurated its Digital Centre of Excellence in Pune, India. This milestone strengthens Roche’s presence in India and demonstrates the company’s active commitment to building a hub for digital talent and thought leadership in healthcare.
Biotech and research labs are increasingly adopting lab automation instruments to achieve high-throughput analysis, enhance accuracy, and minimize human error in diagnostics and research. The growing focus on personalized medicine and faster drug discovery is accelerating this shift. Developers are advancing robotics, AI, and microfluidics to optimize workflows and boost productivity. Laboratories are also prioritizing standardized, reproducible results and operational efficiency, which further motivates them to integrate automated systems into their processes. For instance, in April 2025, QIAGEN planned to launch three new sample preparation instruments to expand and enhance its automated sample preparation portfolio. These systems aim to bring greater efficiency and sustainability to laboratory workflows.
To learn more about this report, Download Free Sample
North America holds the largest market share of 47.20% in 2025. Strong research infrastructure, high healthcare spending, and widespread adoption of advanced technologies are driving steady growth in the North America biotechnology instruments market. Government and private sector investments actively support innovation in genomics, diagnostics, and personalized medicine. Leading industry players continue to expand their product portfolios through collaborations and acquisitions. Biotech companies, research institutions, and academic centers in the region are fueling increasing demand for these instruments.
For instance, Otometrics, a global manufacturer of audiology instrumentation and software solutions, has launched the next-generation Bio-logic® solutions. Working in collaboration with its technology partner, Germany-based PATH MEDICAL, Otometrics is delivering four modular solutions that are integrated into its product family in Tennessee.
European healthcare systems are actively focusing on personalized treatment strategies. Hospitals and laboratories are integrating cutting-edge biotechnology instruments that enable genetic and molecular analysis to deliver precise diagnostics and therapies. Regulatory bodies like the European Medicines Agency (EMA) set clear guidelines to ensure the safety and effectiveness of these instruments. This supportive regulatory environment drives innovation and motivates manufacturers to develop high-quality, compliant products that meet stringent standards. For instance, in September 2024, Thermo Fisher Scientific’s PPD™ clinical research business, announced that it is expanding its global laboratory services by opening a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden. The lab will provide pharmaceutical and biotech customers with advanced laboratory services and state-of-the-art instrumentation.
U.S. companies develop automated lab systems, AI-powered analysis, and next-generation sequencing instruments that boost research throughput, precision, and efficiency. Laboratories and healthcare providers rely on these innovations to meet the rising demand for faster, more accurate biotechnological analyses. The U.S. healthcare system actively integrates biotechnology instruments for personalized diagnostics and therapies. Increased use of genetic and molecular testing supports targeted treatments, enhances patient outcomes, and drives demand for advanced analytical tools. For instance, in January 2025, the U.S. Department of Commerce announced that it will implement new export controls on specific biotechnology equipment, citing national security concerns related to artificial intelligence and data science.
The Indian government drives biotechnology growth through initiatives such as the Biotechnology Industry Research Assistance Council (BIRAC) and the “Make in India” campaign. These programs increase funding, build infrastructure, and encourage public-private collaborations, accelerating the nationwide use of advanced biotechnology instruments. At the same time, a growing number of biotech startups focused on diagnostics, agriculture, and environmental solutions are reshaping the industry. Innovation hubs and incubators actively support this growth by demanding compact, cost-effective, and versatile instruments for early-stage research and prototyping, especially in tier 2 and tier 3 cities. For instance, in February 2025, Miltenyi Biotec, a global leader in cell and gene therapy (CGT) solutions, unveiled India’s first dedicated cell and gene therapy center of excellence (CoE) in Hyderabad. The facility includes a showroom showcasing advanced MACS® instruments, a CliniMACS Prodigy® platform for therapy development and manufacturing, and offers interactive training opportunities.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 68.22 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 9.4% | 2032 Value Projection: | USD 127.95 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AngioDynamics, Cynosure, LLC, Lumenis, Candela Medical, Novanta, Inc., Iridex, Alcon, Inc., and Zimmer Biomet, among others |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Biotechnology instruments are experiencing higher demand due to the growing focus on personalized medicine and genomic research. Institutions are investing in advanced tools like DNA sequencers, PCR systems, and microarray analyzers to decode individual genetic profiles. This trend is shaping healthcare by enabling targeted therapies, early disease detection, and tailored treatment plans. As the need for precision increases, laboratories and hospitals continue upgrading their infrastructure with cutting-edge instruments to support genetic analysis and personalized diagnostics.
The biopharmaceutical sector is driving substantial demand for biotechnology instruments across upstream and downstream processing. With the surge in vaccine development, monoclonal antibodies, and biosimilars, manufacturers are relying on fermentation systems, cell counters, and chromatography equipment. These tools help ensure high-yield production, consistent quality, and compliance with international standards. Companies are expanding their manufacturing capabilities, pushing the need for robust instrumentation to scale up processes, improve productivity, and reduce contamination risks in biologics production.
Share
Share
About Author
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
